Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

22.84 -0.50 (-2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,850,418
Open 23.28
Bid (Size) 22.60 (500)
Ask (Size) 23.75 (300)
Prev. Close 23.34
Today's Range 22.61 - 23.50
52wk Range 6.250 - 34.39
Shares Outstanding 88,406,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Executive Chair Transition
From Tango Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+155.8%
+155.8%
1 Month
-16.1%
-16.1%
3 Month
-1.1%
-1.1%
6 Month
+98.1%
+98.1%
1 Year
+242.9%
+242.9%

More News

Read More
News headline image
Tango Therapeutics Appoints Robert Azelby to Board of Directors
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Proposed $500 Million Public Offering
From Tango Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
Via The Motley Fool
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Via The Motley Fool
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Tango Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tango Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tango Therapeutics, Inc. - Common Stock trade on?
Tango Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tango Therapeutics, Inc. - Common Stock?
The ticker symbol for Tango Therapeutics, Inc. - Common Stock is TNGX on the Nasdaq Stock Market
What is the current price of Tango Therapeutics, Inc. - Common Stock?
The current price of Tango Therapeutics, Inc. - Common Stock is 22.84
When was Tango Therapeutics, Inc. - Common Stock last traded?
The last trade of Tango Therapeutics, Inc. - Common Stock was at 08/31/26 04:00 PM ET
What is the market capitalization of Tango Therapeutics, Inc. - Common Stock?
The market capitalization of Tango Therapeutics, Inc. - Common Stock is 2.02B
How many shares of Tango Therapeutics, Inc. - Common Stock are outstanding?
Tango Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.